PharmaShots Weekly Snapshots (August 02 – 06, 2021)

Medtronic to Acquire Intersect ENT for ~$1.1B

Published: Aug 6, 2021 | Tags: Medtronic, Intersect ENT, ~$1.1B

Kite Signs a License Agreement with Appia to Develop Allogeneic Cell Therapies for the Treatment of Cancer

Published: Aug 6, 2021 | Tags: Kite, Appia, Allogeneic Cell Therapies, Cancer

Polpharma & Bioeq Report BLA Submission to the US FDA for FYB201 (biosimilar, ranibizumab)

Published: Aug 6, 2021 | Tags: Polpharma, Bioeq, BLA, FDA, FYB201, biosimilar, ranibizumab

Takeda Publishes the Results of Takhzyro (lanadelumab) in P-III HELP Study for the Prevention of Hereditary Angioedema Attacks in the Journal Allergy

Published: Aug 6, 2021 | Tags: Takeda, Takhzyro, lanadelumab, P-III, HELP OLE Study, Hereditary Angioedema Attacks, Allergy

AstraZeneca Signs an Exclusive License Agreement with Sierra for AZD5153 to Treat Myelofibrosis

Published: Aug 6, 2021 | Tags: Sierra, AstraZeneca, AZD5153, Myelofibrosis

Bayer to Acquire Vividion for ~$2B

Published: Aug 6, 2021 | Tags: Bayer, Vividion, Drug Discovery Platform, ~$2B

Merck’s Keytruda (pembrolizumab) Receives the US FDA’s Priority Review for the Adjuvant Treatment of Stage II

Published: Aug 5, 2021 | Tags: Merck, Keytruda, pembrolizumab, P-III, KEYNOTE-716 Trial, Stage II, Resected High-Risk Melanoma

Regeneron and Sanofi Stop P-III EMPOWER-Lung 3 Trial Early Due to Improvement in OS for 1L Treatment of NSCLC

Published: Aug 5, 2021 | Tags: Regeneron, Sanofi, P-III, EMPOWER-Lung 3 Trial, Libtayo, Platinum-Doublet CT, NSCLC

Regeneron Publishes the Results of REGEN-COV (casirivimab and imdevimab) in P-III Trial to Prevent COVID-19 at NEJM

Published: Aug 5, 2021 | Tags: Regeneron, REGEN-COV, casirivimab, imdevimab, P-III, Trial, COVID 19, NEJM

Pfizer Reports Results of Ritlecitinib in P-IIb/III Trial for the Treatment of Alopecia Areata

Published: Aug 5, 2021 | Tags: Pfizer, Ritlecitinib, P-IIb/III, Trial, Alopecia Areata

Schrödinger Signs a R&D Collaboration with Zai Lab for Oncology Program Targeting DNA Damage Response

Published: Aug 5, 2021 | Tags: Schrödinger, Zai Lab, Oncology program, DNA damage response

F-star Collaborates with MSD to Evaluate FS120 + Keytruda for the Treatment of Cancer

Published: Aug 5, 2021 | Tags: F-star, MSD, FS120, Keytruda, Cancer

BeyondSpring Reports Results of Plinabulin + Docetaxel in P-III DUBLIN-3 Trial for 2L and 3L Treatment of NSCLC with EGFR Wild Type

Published: Aug 4, 2021 | Tags: BeyondSpring, Plinabulin, Docetaxel, P-III, DUBLIN-3 Trial, NSCLC, EGFR Wild Type

Outlook Reports Results of ONS-5010 / Lytenava (bevacizumab-vikg) in P-III NORSE TWO Trial for the Treatment of Wet AMD

Published: Aug 4, 2021 | Tags: Outlook, ONS-5010, Lytenava, bevacizumab-vikg, P-III, NORSE TWO Trial, Wet AMD

Celltrion to Supply Herzuma (biosimilar, trastuzumab) and Truxima (biosimilar, rituximab) in Brazil

Published: Aug 4, 2021 | Tags: Celltrion, Herzuma, biosimilar, trastuzumab, Truxima, rituximab, Brazil

Tachyon Collaborates with AbCellera to Develop Novel Antibody Therapies Targeting TGF-β Superfamily Member for Cancer

Published: Aug 4, 2021 | Tags: Tachyon, AbCellera, Novel Antibody Therapeutic, TGF-β Superfamily Member, Cancer

Bayer Reports Results of Eliapixant (BAY1817080) in P-IIb Study for the Treatment of Refractory Chronic Cough

Published: Aug 4, 2021 | Tags: Bayer, Eliapixant, BAY1817080, P-IIb, Study, Refractory Chronic Cough

Marinus Signs an Agreement with Orion for the Commercialization of Ganaxolone in EU

Published: Aug 4, 2021 | Tags: Marinus, Orion, Ganaxolone, EU

Lilly and Incyte Report Results of Baricitinib in P-III COV-BARRIER Study for Patients with COVID-19 Receiving Invasive Mechanical Ventilation

Published: Aug 3, 2021 | Tags: Lilly, Incyte, Baricitinib, P-III, COV-BARRIER Study, COVID 19

UCB’s Bimekizumab Receives NICE Recommendation for the Fast-Track Appraisal to Treat Severe Plaque Psoriasis

Published: Aug 3, 2021 | Tags: UCB, Bimekizumab, NICE Recommendation, Severe Plaque Psoriasis

Novartis Lifts Partial Clinical Trial Hold on OAV-101 Clinical Program to Treat SMA

Published: Aug 3, 2021 | Tags: Novartis, Partial, Clinical Trial Hold, OAV-101, SMA

Roche Reports the US FDA’s Acceptance of BLA and Priority Review of Tecentriq (atezolizumab) as an Adjuvant Treatment for NSCLC

Published: Aug 3, 2021 | Tags: Roche, US, FDA, BLA, Priority Review, Tecentriq, atezolizumab, NSCLC

Sanofi to Acquire Translate Bio for ~$3.2B

Published: Aug 3, 2021 | Tags: Sanofi, Translate Bio, ~$3.2B

Abbott Launches Jot Dx Insertable Cardiac Monitor to Detect Abnormal Heart Rhythms in US

Published: Aug 3, 2021 | Tags: Abbott, Jot Dx, Insertable Cardiac Monitor, Abnormal Heart Rhythms, US

Regeneron Reports the EUA Expansion for REGEN-COV (casirivimab and imdevimab) to Treat COVID 19

Published: Aug 2, 2021 | Tags: Regeneron, EUA, REGEN-COV, casirivimab, imdevimab, COVID 19

Ipsen Signs an Exclusive Collaboration with Exicure to Develop SNA-Based Therapeutics for Rare Neurodegenerative Disorders

Published: Aug 2, 2021 | Tags: Ipsen, Exicure, SNA-Based Therapeutics, Rare Neurodegenerative Disorders

Janssen’s Uptravi (selexipag) Receives the US FDA’s Approval for IV Use in Adults with Pulmonary Arterial Hypertension

Published: Aug 2, 2021 | Tags: Janssen, UPTRAVI, selexipag, US, FDA, Approval, Pulmonary Arterial Hypertension

AstraZeneca’s Saphnelo (anifrolumab-fnia) Receives the US FDA’s Approval for the Treatment of Moderate to Severe Systemic Lupus Erythematosus

Published: Aug 2, 2021 | Tags: AstraZeneca, Saphnelo, anifrolumab-fnia, US, FDA, Approval, Systemic Lupus Erythematosus

Takeda and Frazier Collaborate to Launch HilleVax (biopharma company) for the Development of Norovirus Vaccine

Published: Aug 2, 2021 | Tags: Takeda, Frazier, HilleVax, biopharma company, HIL-214

Astellas Signs a License Agreement with Minovia for Novel Mitochondrial Cell Therapy Programs

Published: Aug 2, 2021 | Tags: Astellas, Minovia, Mitochondrial Cell Therapy Programs

Related Post: PharmaShots Weekly Snapshots (July 26 – 30, 2021)